<DOC>
	<DOCNO>NCT02953314</DOCNO>
	<brief_summary>This Phase 3 , 2-part ( Part A Part B ) , open label , multicenter study evaluate PK , safety , tolerability multiple dose VX-661 combination ivacaftor subject 6 11 year age CF homozygous heterozygous F508del-CFTR mutation .</brief_summary>
	<brief_title>A Study Evaluate Pharmacokinetics , Safety , Tolerability VX-661/Ivacaftor Pediatric Subjects With Cystic Fibrosis</brief_title>
	<detailed_description />
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Cystic Fibrosis</mesh_term>
	<criteria>Subjects weigh ≥15 kg without shoe Screening Visit . All genotype specify study protocol eligible Part A . The following genotype eligible Part B : homozygous F508del CFTR mutation heterozygous F508del CFTR mutation second allele CFTR mutation predict residual function . heterozygous F508del CFTR mutation second CFTR allele gate defect clinically demonstrated ivacaftor responsive Subjects confirm diagnosis CF define sweat chloride value ≥60 mmol/L chronic sinopulmonary and/or gastrointestinal disease consistent diagnosis CF . Subjects homozygous F508delCFTR mutation must sweat chloride value ≥60 mmol/L . Subjects ppFEV1 ≥40 percentage point Screening Visit Subjects stable CF disease deem investigator Screening Visit . Subjects willing remain stable CF medication regimen Day 14 ( Part A ) Week 24 ( Part B ) , applicable , Safety Follow Visit . Subjects able swallow tablet . Female subject childbearing potential must negative serum pregnancy test Screening Visit negative urine pregnancy test Day 1 Visit receive first dose study drug . Subjects childbearing potential sexually active must meet contraception requirement History comorbidity review Screening Visit , opinion investigator , might confound result study pose additional risk administer study drug subject . Any clinically significant laboratory abnormality Screening Visit would interfere study assessment pose undue risk subject . An acute upper low respiratory infection , pulmonary exacerbation , change therapy pulmonary disease within 28 day Day 1 Colonization organisms associate rapid decline pulmonary status . A standard 12 lead ECG demonstrate QTc &gt; 450 msec Screening Visit . History solid organ hematological transplantation Screening Visit . Ongoing prior participation investigational drug study use commercially available CFTR modulator ( except physicianprescribed Kalydeco approve indication ) within 30 day screen . Use restrict medication food within specify duration Screening Visit first dose study drug and/or unwillingness maintain restriction . History evidence cataract , lens opacity , Ysuture , lamellar ring determine clinically significant ophthalmologist ophthalmologic examination Screening Visit . Pregnant nursing female .</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>11 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>